Tolerance and response of afatinib combined with tegafur in patients with advanced biliary tract cancer after failure of gemcitabine-based systemic therapy.

Discov Oncol · 2026 · PMC13222911 · PMID 42001372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

TJ-14 showed a trend in reducing the risk of afatinib-induced diarrhea, and minocycline reduced the risk of afatinib-induced skin rash [ 49 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.